RWE 201 – South Korea’s Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development
South Korea has several initiatives to support healthcare and drug development using real-world evidence (RWE). The country’s regulatory bodies, government organizations, industry and academia leaders, and patient groups have started discussions to develop draft guidance for integrating RWE with reimbursement and regulatory decisions [1][2].
The Ministry of Food and Drug Safety (MFDS) in South Korea has recently issued guidelines on the use of RWE in regulatory decision-making, with a focus on the use of real-world data (RWD) to support clinical trial design and post-market surveillance [3]. In June 2021, the MFDS published the Guideline for Medical Information Database Research, which focuses on utilizing RWE that analyzed RWD, such as national health insurance data and electronic medical records, for post-marketing safety studies [4].
Moreover, the Korea Comprehensive Plan for Drug Safety Management (2020-2024) anticipates that the MFDS will continue to build a local ecosystem to leverage innovative technology, including RWE, to support new drug development [4].
In addition to these initiatives, an increasing number of studies are using healthcare claims databases to generate RWE for the effectiveness and safety of clinical therapeutics in South Korea [5]. These databases provide a rich source of RWD, which can be used to generate RWE for potential risk and benefit assessments derived from sources other than randomized controlled trials (RCTs) [5].
In summary, South Korea is actively working on leveraging RWE to support healthcare and drug development, with a focus on integrating RWE into regulatory and reimbursement decisions, supporting clinical trial design, post-market surveillance, and safety studies.
References:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405531/
[2] https://www.sciencedirect.com/science/article/pii/S0149291822000170
[3] https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/
[4] https://globalforum.diaglobal.org/issue/june-2022/real-world-evidence-regulatory-landscape-in-asia-pacific-australia-china-japan-south-korea-and-taiwan/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272364/
Share this story...
Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations
RWE 201 - Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) [...]
RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?
RWE 201 - RWE Guest Post - Does real-world evidence play a role in G-BA's benefit assessments in Germany? Guest: Anja PownellGerman Market Access – Simplified: https://germanmarketaccesssimplified.com/IntroductionThe German [...]
RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA
RWE 201 - RWE Guest Post – Germany - From Concept to Evaluation: The Journey of RWE requests by the G-BA Guest: Anja PownellGerman Market Access – Simplified: [...]
Spain – Championing the Ethical and Responsible Use of Real World Data
RWE 201 - Spain – Championing the Ethical and Responsible Use of Real World Data Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdfIn 2022, the Spanish Data Protection Agency (AEPD) gave its [...]
EU – RWD/RWE is Embedded into the New EU Medicines Regulations
RWE 201 - EU – RWD/RWE is Embedded into the New EU Medicines Regulations Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_enIn 2023, the European Commission undertook an ambitious overhaul of [...]
EU – EU’s Action Plan for Real-World Data (RWD) & RWE
RWE 201 - EU – EU's Action Plan for Real-World Data (RWD) & RWE The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) [...]
